Blackpool CCG medicines optimisation

Blackpool CCG medicines optimisation

Medicines play an important part in promoting well-being, preventing ill health and managing disease. Over 700 million prescription items are dispensed in England each year with a cost approaching £8billion.

Medicines management can be defined in several ways:

  • The clinical, cost-effective, safe and secure handling of medicines
  • A system of processes and behaviours that determines how medicines are used by the NHS and patients
  • Enabling people to make the best possible use of medicines
  • Our goal is to achieve the best health outcomes for patients where medicines are involved.

If you have any medicines queries please contact NHS Blackpool CCG’s medicines management team on 01253 951306 or email blackpool.medicinesoptimisation@nhs.net


 

Click each header to expand its content

Medicines RAG list

Please see the links below for background information on the Red, Amber, Green (RAG) classification in relation to prescribing responsibility and also our RAG list of drugs.

Prescribing position statements

NameSizeHits
28 Day Prescribing 0.3 MB167
Camouflaging Products 0.2 MB22
Cannabis based medicinal products for pain POSITION STATEMENT 0.3 MB151
Clinical Need Low Priority Medicines - General 0.3 MB283
Clinical Need Soluble Analgesics 0.5 MB206
Clinical Need Thickeners Position Statement 0.3 MB135
Commercial sponsorship and joint working with the pharmaceutical industry 0.6 MB120
Denosumab Position Statement 0.3 MB112
E-Cigarettes-Position-Statement-v2.0-FINAL-FOR-LMMG-WEBSITE[1] 0.2 MB156
Edoxaban Position Statement 0.2 MB130
Emollients and Sunscreens 0.2 MB220
Free of Charge (FOC) Medicines schemes 0.3 MB116
Generic Biosimilar Medicines Position Statement 0.2 MB122
Generic Prescribing Guidelines 0.3 MB216
Glucose Monitoring Devices 0.5 MB172
Gluten Free Foodstuffs 0.2 MB137
Health Professionals e-cigarettes briefing 0.2 MB102
Holiday Medication 0.2 MB186
Liothyronine 0.2 MB113
Ophthalmology Macular Pathways 1.1 MB119
Oral Nutritional Supplements (ONS) in care and nursing homes 0.2 MB182
Out of Area Prescribing 0.2 MB86
Policy for the Provision of Insulin Pumps for Patients with Diabetes Mellitus 0.3 MB153
Position Statement OPIOID PRESCRIBING max dose Final Version 1.1 0.1 MB13
Position Statement Sip Feeds 0.4 MB129
Prescribing Nutritional Supplements Post Bariatric Surgery 0.3 MB129
Prescribing of multivitamins and phenylalanine-free amino acid substitutes for adults and children with phenylketonuria (PKU) 0.7 MB107
Prescribing Vitamins And Minerals 0.3 MB109
Prophylactic supply of catheters post pelvic organ prolapse 0.2 MB98
Stoma Care Products - deodorants and air fresheners 0.4 MB139
Trans Anal Irrigation Devices 0.2 MB110
Vitamin D Position Statement 0.2 MB49
Zero Risk Schemes 0.3 MB102

Prescribing guidance

NameSizeHits
Asthma treatment guideline for children version 0.4 MB11
Blood glucose meters and test strips Type 2 Diabetes V2.3 0.5 MB273
Cannabis-based-medication-desk-guide-Nov-2018 December-Edit 0.6 MB123
Chronic Non-cancer Pain Guidelines 0.7 MB102
Colomycin prescribing information sheet Non CF indications. 0.2 MB84
Constipation-Pathway-Version 0.7 MB182
dementia medicines information sheet 0.3 MB2
Diabetes - Glucagon Like Peptide Contract 0.2 MB134
Diabetes - Home Monitoring of Blood Glucose Levels Guideline 0.2 MB138
DIABETES Algorithm-for-antihyperglycaemic-therapy-in-adults-with-type-II-v1.5[1] 0.5 MB120
Diabetes-self-management-contract 0.5 MB169
Edoxaban Prescribing Tip 68 KB169
Erectile-Dysfunction-Guideline-Version 1.0 MB141
Flash Glucose Monitoring policy - L&SC 0.2 MB92
Gastroenterology-Biologics-Pathway-Version 0.4 MB143
Good-practice-guidelines-for-Gender-Dysphoria 0.6 MB113
Gout-Prescribing-Guidance-Version-1.2-FOR-WEBSITE 0.7 MB205
Guidance for Prescribing Second Generation Long Acting Antipsychotic Injections 0.6 MB65
Headache Management Guideline for Adults 0.7 MB81
Hydroxychloroquine-prescriber-information-sheet-v.1.0-FOR-WEBSITE 0.5 MB100
Insulin Toujeo Information Sheet and Good Practice Guide 0.3 MB65
Interim Gender Dysphoria protocol 0.6 MB99
Lancashire and South Cumbria Self-Care and Acces to OTC Medicines – Temp... 83 KB3
LMMG-Psoriasis-guideline-FOR-WEBSITE 0.5 MB187
LSCMMG OTC Items that Should not be Routinely Prescribed in Primary Care... 0.2 MB12
Management-of-Behavioural-and-Psychological-Symptoms-of-Dementia-Primary-Care-Summary-Document 0.2 MB132
Mgt-of-Infection-Primary-Care-Guidance-January-2017 0.7 MB214
Neuropathic Pain Guidance (Version 1.2) 0.9 MB128
NWC-SCN01-Clinical-Practice-Summary-Palliative-Care-Final-version 0.6 MB122
Pathway For The Prevention Of Stroke And Systemic Embolism In Non Valvular Atrial Fibrillation Plus TIA 0.8 MB104
Prescription-Management-of-Stoma-and-Continence-Products-Version-1.1-FINAL-FOR-WEBSITE 0.6 MB140
Primary Care Good Prescribing Guide 0.6 MB221
Primary Care Responsibilities in Prescribing and Monitoring Hormone Therapy 0.3 MB115
Psoriasis LMMG Biologic and High Cost Drug Commissioning Pathway v-1.6[1] 0.4 MB161
Psoriatic-Arthritis-Recommended-Treatment-Pathway-Version 0.3 MB140
RA-High-Cost-Drugs-Pathway-v 0.2 MB131
Restless Legs Syndrome guidelines 0.3 MB81
Rheumatoid Arthritis Pathway Guideline 0.1 MB14
SIP Feeds 0.1 MB152
Trans male prescribing information sheet 0.2 MB34
Trans-female-gender-dysphoria-prescribing-information-sheet-version-1.1[1] 0.2 MB19
Wound care formulary 8.2 MB212

SHARED CARE: Guidelines and information documents

Where shared care has been agreed between prescribers, this section includes documents to support clinicians in clarifying their responsibilities around prescribing and drug/patient monitoring, where relevant.

DMARDs-Shared-Care-Agreement-V1.1 (docx | 0.1 MB)

For drugs listed in the GP+ scheme below, please refer to the GP+ specification (Standard 10: Shared Care). Since drugs may be added to the list in-year, the list below will be the most up-to-date, rather than those listed in the current 2017/18 GP+ document.

Drugs included in GP+ scheme

Drugs not included in GP+ scheme

Patient Group Directions

A Patient Group Direction (PGD) is a written direction that allows the supply and/or administration of a specified medicine(s), by named authorised health professionals, to a well-defined group of patients requiring treatment for a specific condition. The patient must always fit the defined criteria and organisations must ensure that healthcare professionals supplying and/or administering medicines under a PGD are fully trained, competent individuals who are authorised to do so.

Organisations must be in possession of PGDs that are appropriately signed and fully authorised, unsigned copies are not the legal document and are for information purposes only.

Cumbria and Lancashire CCGs have a collaborative arrangement to produce the PGDs for the national vaccination programme.

Vaccine and immunisation PGDs: The signed copies of these PGDs have been distributed to organisations and GP practices. Each organisation or practice is required to keep the signed copy and ensure all health professionals who will be working under it are authorised and have signed the second page under the managerial content section. The documents at the following link are for information only and are not the legal document: www.lancsmmg.nhs.uk/pgds

Patient information leaflets

Primary Care Rebate Schemes

Primary care rebate schemes are contractual arrangements offered by pharmaceutical companies, or third party companies, which offer retrospective financial rebates to the CCG on GP prescribing expenditure for particular branded medicine(s). The availability of a scheme does not influence the inclusion of specific medicines in care pathways or formularies.

Current Primary Care Rebate Schemes in place:

  • Clenil Modulite (Beclometasone) – Started July 2019
  • Fencino (Fentanyl) – Started October 2018
  • Firmagon (Degarelix) – Started September 2016
  • Januvia (Sitagliptin)  – Started September 2018
  • Lixiana (Edoxaban) – Started October 2018
  • Longtec (Oxycodone SR) – Started July 2019
  • Sereflo (Fluticasone / Salmeterol) – Started June 2019
  • Seretide (Fluticasone / Salmeterol) – Started January 2018
  • Spiolto (Tiotropium + Olodaterol) – Started October 2018
  • Xarelto (Rivaroxaban) – Started July 2019
  • Zoladex (Goserelin) – Started January 2019

Last updated on 18 December 2019 at 11:11 by Senior communications and engagement officer N